← Back to Search

Other

Hyperpolarized Pyruvate (13C) for Prostate Cancer

Phase 1
Waitlist Available
Led By Charles Cunningham, PhD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will study the effects of radium 223 on men with CRPC.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Images of lactate, bicarbonate and pyruvate in patients with bone-metastatic CRPC measured by MRI

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI w/ Hyperpolarized Pyruvate (13C)Experimental Treatment1 Intervention
"Hyperpolarization" of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,551,435 Total Patients Enrolled
34 Trials studying Prostate Cancer
12,636 Patients Enrolled for Prostate Cancer
Charles Cunningham, PhDPrincipal InvestigatorSunnybrook Research Institute
5 Previous Clinical Trials
269 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings in this clinical trial currently?

"The clinical trial, which was first uploaded to clinicaltrials.gov on December 15th 2016 and last updated on May 4th 2022, is actively searching for participants."

Answered by AI

What is the current enrollment quota for this trial?

"Affirmative. Clinicaltrials.gov attests to the fact that this investigation is actively recruiting patients, with a listing initially posted on December 15th 2016 and last updated in May 4th 2022. 30 people are required for participation from one site."

Answered by AI

Is Hyperpolarized Pyruvate (13C) relatively innocuous for patients?

"Due to the limited evidence surrounding its safety and efficacy, Hyperpolarized Pyruvate (13C) was assigned a rating of 1 on our team's scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
2016. "Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02844647.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top